Sponsored Listings

Orthogate arrow News arrow Literature arrow Voluntary withdrawal of Vioxx from the U.S. market due to safety concerns
Voluntary withdrawal of Vioxx from the U.S. market due to safety concerns PDF Print E-mail
Written by christian   
Thursday, 30 September 2020
The FDA published the message shown below pertaining to Voixx.
Further information will be posted on cma.ca and can be found by following this link:
http://www.cma.ca/index.cfm?ci_id=367&la;_id=1&alert;=1
to the cma.ca drug information section.

-------------------------------------------
FDA Public Health Advisory: Safety of Vioxx
-------------------------------------------
Merck & Co., Inc. today announced a voluntary withdrawal of Vioxx from the U.S. market due to safety concerns. Vioxx is a prescription COX-2 selective, non-steroidal anti-inflammatory drug (NSAID) that was approved by FDA in May 1999 for the relief of the signs and symptoms of osteoarthritis, for the management of acute pain in adults, and for the treatment of menstrual symptoms.
It is also approved for the relief of the signs and symptoms of rheumatoid arthritis in adults and children.

The Agency was informed by Merck & Co., Inc. on September 27, 2004, that the Data Safety Monitoring Board for an ongoing long-term study of Vioxx (APPROVe) had recommended that the study be stopped early for safety reasons. The study was being conducted in patients at risk for developing recurrent colon polyps. The study showed an increased risk of cardiovascular events (including heart attack and
stroke) in patients on Vioxx compared to placebo, particularly those who had been taking the drug for longer than 18 months. Based on this new safety information, Merck and FDA officials met the next day, September 28, 2004, and during that meeting FDA was informed that Merck was voluntarily withdrawing Vioxx from the market place.

The risk that an individual patient taking Vioxx will suffer a heart attack or stroke related to the drug is very small. Patients who are currently taking Vioxx should contact their physician for guidance regarding discontinuation and alternative therapies.
Last Updated ( Saturday, 16 July 2020 )
Submit Community News
If you have some orthopedic news that you would like to share with the community, please submit your story, article, announcement or review here.